Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSMA-914
- Development stage
- Unknown
- Lead developer
- German Cancer Research Center
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PSMA-914 is a dual-modality (hybrid) imaging agent designed for the detection and surgical management of prostate cancer. It is derived from the scaffold of the established PET tracer PSMA-11, incorporating both a chelator (HBED-CC) for radiolabeling with Gallium-68 and a near-infrared fluorescent dye (IRDye800CW). This hybrid design allows for preoperative staging and lesion localization via PET/CT imaging, followed by real-time intraoperative visualization of tumor margins and lymph node metastases using fluorescence-guided surgery. The molecule specifically targets the Prostate-Specific Membrane Antigen (PSMA), also known as glutamate carboxypeptidase II, which is highly overexpressed on the surface of prostate cancer cells.
- Other names
- 68Ga-PSMA-914PSMA-11-IRDye800CW hybridPSMA11-IRDye800CW hybridPSMA 11-IRDye800CW hybrid
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on PSMA-914.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSMA-914.